Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07166393 · ClinicalTrials.gov registry record · Phase 2
Valproic AcId for Traumatic BRAin INjury Trial
A Phase 2 study, sponsored by Northwestern University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 432
- Enrollment target
NCT07166393 is a Phase 2 study that has not yet begun recruiting, run by Northwestern University. The registered enrollment target is 432 participants.
The verdict
NCT07166393, a Phase 2 study, has not yet begun recruiting, sponsored by Northwestern University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 432 participants
- Enrollment target
Study Summary
The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI). Patients with moderate to severe TBI will randomly receive either: 1. Standard of care treatment and normal saline 2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose
Interventions
- DRUG Valproic Acid (VPA)
- OTHER Standard of care treatment + normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2026-05 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07166393
The ClinicalTrials.gov registry entry for NCT07166393 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valproic Acid (VPA) is the first listed.
NCT07166393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07166393 about?
NCT07166393 is a clinical study titled "Valproic AcId for Traumatic BRAin INjury Trial". The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI). Patients with moderate to severe TBI will randomly receive either: 1. Standard of care treatment and normal sali...
What is the current status of trial NCT07166393?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 432 participants. The study started on 2026-05. Estimated completion is 2030-12.
What interventions are being tested in trial NCT07166393?
The interventions under investigation include: Valproic Acid (VPA) (DRUG), Standard of care treatment + normal saline (OTHER).
Who is sponsoring clinical trial NCT07166393?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.